Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lin-_CD34_CD133_profiling

ABSTRACT: Stem/progenitor cells demonstrate neuro-regenerative potential that is dependent upon their humoral activity by producing various trophic factors that regulate cell migration, growth, and differentiation. To better characterise the human umbilical cord blood-derived stem/progenitor cells, we analyzed the global gene expression pattern in the lineage-negative, CD34+, CD133+ cells and unseparated nucleated cells. We were interested in biological processes concerning biosynthetic processes, cytokine production, secretion by cells, chemotaxis, migration, and proliferative capacities.

ORGANISM(S): Homo sapiens

SUBMITTER: Edyta Paczkowska

PROVIDER: E-MTAB-2053 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Humoral activity of cord blood-derived stem/progenitor cells: implications for stem cell-based adjuvant therapy of neurodegenerative disorders.

Paczkowska Edyta E Kaczyńska Katarzyna K Pius-Sadowska Ewa E Rogińska Dorota D Kawa Miłosz M Ustianowski Przemysław P Safranow Krzysztof K Celewicz Zbigniew Z Machaliński Bogusław B

PloS one 20131231 12

<h4>Background</h4>Stem/progenitor cells (SPCs) demonstrate neuro-regenerative potential that is dependent upon their humoral activity by producing various trophic factors regulating cell migration, growth, and differentiation. Herein, we compared the expression of neurotrophins (NTs) and their receptors in specific umbilical cord blood (UCB) SPC populations, including lineage-negative, CD34(+), and CD133(+) cells, with that in unsorted, nucleated cells (NCs).<h4>Methods and results</h4>The expr ...[more]

PMID: 24391835

Similar Datasets

Transcription factor ChIP-seq in expanded human hematopoietic stem and progenitor cells

Project description:While many individual transcription factors are known to regulate hematopoietic differentiation, major aspects of the global architecture of hematopoiesis remain unknown. Here, we profiled gene expression in 38 distinct purified populations of human hematopoietic cells and used probabilistic models of gene expression and analysis of cis-elements in gene promoters to decipher the general organization of their regulatory circuitry. We identified modules of highly co-expressed genes, some of which are restricted to a single lineage, but most are expressed at variable levels across multiple lineages. We found densely interconnected cis-regulatory circuits and a large number of transcription factors that are differentially expressed across hematopoietic states, suggesting a more complex regulatory system than previously assumed. We functionally validated a subset of candidate factors using RNA interference and ChIP-Seq. Our dataset, analytic tools, and findings, available on a web-based portal, provide a unique resource to study the regulatory architecture of hematopoiesis. Human CD133-positive Umbilical Cord Blood (UCB) cells were cross-linked with formaldehyde for 20 min. DNA was enriched by chromatin immunoprecipitation (ChIP) and analyzed by Solexa sequencing. A sample of whole cell extract (WCE) was sequenced and used as the background to determine enrichment. ChIP was performed using an antibody against total TAL1 (Santa Cruz SC-12984), PU.1/SPI1 (Santa Cruz SC-352X), IKAROS (Santa Cruz SC-9859X) and MEIS1 (Abcam ab19867). This submission represents the ChIP-seq component of the study.

2011-01-26 | E-GEOD-26014 | biostudies-arrayexpress

Chromatin marks and RNA Pol II in human hematopoietic stem and progenitor cells

Project description:The transcriptional status of genes can be determined from the enrichment pattern of RNA polymerase at the transcription start site (TSS) and across the body of the gene. Active elongating genes are enriched for H3K79me2, and Polycomb paused genes are marked by H3K27me3. Human CD133-positive Umbilical Cord Blood (UCB) cells were cross-linked with formaldehyde for 20 min. DNA was enriched by chromatin immunoprecipitation (ChIP) and analyzed by Solexa sequencing. A sample of whole cell extract (WCE) was sequenced and used as the background to determine enrichment. ChIP was performed using an antibody against total RNA Pol2 (Covance 8WG16), H3K27me3 (Abcam ab6002) and H3K79me2 (Abcam ab3594).

2011-01-31 | E-GEOD-26015 | biostudies-arrayexpress

PRC2 inhibition counteracts the culture-associated loss of engraftment potential of human cord blood-derived hematopoietic stem and progenitor cells

Project description:Cord blood hematopoietic stem cells (CB-HSCs) are an outstanding source for transplantation approaches. However, the amount of cells per donor is limited and culture expansion of CB-HSCs is accompanied by a loss of engraftment potential. In order to analyze the molecular mechanisms leading to this impaired potential we profiled global and local epigenotypes during the expansion of human CB hematopoietic stem and progenitor cells (HPSCs). Human CB-derived CD34+ cells were cultured in serum-free medium together with SCF, TPO, FGF, with or without Igfbp2 and Angptl5 (STF/STFIA cocktails). As compared to the STF cocktail, the STFIA cocktail maintains in vivo repopulation capacity of cultured CD34+ cells. Upon expansion, CD34+ cells genome-wide remodel their epigenotype and depending on the cytokine cocktail, cells show different H3K4me3 and H3K27me3 levels. Expanding cells without Igfbp2 and Angptl5 leads to higher global H3K27me3 levels. ChIPseq analyses reveal a cytokine cocktail-dependent redistribution of H3K27me3 profiles. Inhibition of the PRC2 component EZH2 counteracts the culture-associated loss of NOD scid gamma (NSG) engraftment potential. Collectively, our data reveal chromatin dynamics that underlie the culture-associated loss of engraftment potential. We identify PRC2 component EZH2 as being involved in the loss of engraftment potential during the in vitro expansion of HPSCs. 6 samples were hybridized GeneChip Human Gene 1.0 ST Arrays (Affymetrix)

2015-08-07 | E-GEOD-58461 | biostudies-arrayexpress

Transcriptome Study of CD34+ hematopoietic progenitor from patients reached of Primary Myelofibrosis

Project description:An increased number of circulating CD34+ hematopoietic progenitors (HP) and a prominent amplification of dystrophic megakaryocytes (MK) are observed in PMF patients. As transcriptome data from CD34+ hematopoietic progenitors showed modulations of FLT3 and MAP kinase expression independently of the JAK2V617F mutation status Transcriptome analysis was performed on circulating CD34+ cells from PMF patients using Agilent 22K microarray and compared to CD34+ cells from blood and bone marrow from un-mobilized healthy donors. Indirect map: each tested sample was hybridzed with reference probe

2008-07-29 | E-GEOD-12234 | biostudies-arrayexpress

Genome-wide analysis of B lymphocytes derived from human pluripotent stem cells, neonatal and adult sources

Project description:The aim of the array was to compare iPS-derived CD19+CD10+ B cells with B cells from umbilical cord blood (UCB) and adult peripheral blood (PB) iPS-CD34+ cells and UCB-CD133+ cells were differentiated to the B cell lineage in vitro. B cells were also isolated directly from UCB and PB. RNA was extracted from CD19+CD10+ FACS isolated cells from all 4 B cell samples as well as from undifferentiated iPS cells.

2014-06-20 | E-GEOD-53572 | biostudies-arrayexpress

SCI_24h_day3_day7_NCs_profiling

Project description:Peripheral blood -derived nucleated cells from patients with acute spinal cord injury 24h, day 3, day 7 post-injury compared to healthy subjects

2014-02-01 | E-MTAB-2155 | biostudies-arrayexpress

Differential genomic targeting of the transcription factor TAL1 in alternate hematopoietic lineages

Project description:TAL1/SCL is a master regulator of hematopoiesis whose expression promotes opposite outcomes depending on the cell type - differentiation in the erythroid lineage or oncogenesis in the T-cell lineage. Here we used a combination of ChIP-sequencing and gene expression profiling to compare the function of TAL1 in normal erythroid and leukemic T-cells. Analysis of the genome-wide binding properties of TAL1 in these two hematopoietic lineages revealed new insight into the mechanism by which transcription factors select their binding sites in alternate lineages. Our study shows limited overlap in the TAL1 binding profile between the two cell types with an unexpected preference for ETS and RUNX motifs adjacent to E-boxes in the T-cell lineage. Furthermore we show that TAL1 interacts with RUNX1 and ETS1, and that these transcription factors are critically required to target TAL1 to genes that modulate T-cell differentiation. Thus, our findings highlight a critical role of the cellular environment in modulating transcription factor binding, and provide insight into the mechanism by which TAL1 inhibits differentiation leading to oncogenesis in the T-cell lineage. Examine TAL1/SCL binding sites in two different cell lineages (i.e. primary human pro-erythroblasts and the Jurkat T-ALL cell line). These records represent the ChIP-seq part of the study. The gene expresssion part is available at GSE20546.

2010-10-30 | E-GEOD-25000 | biostudies-arrayexpress

Expression by CD133+ cells isolated from the adult human exocrine pancreas

Project description:Expression from CD133+ cells isolated from adult human exocrine tissue was compared to a CD133-depleted cell population Islet-depleted exocrine tissue from three independent adult human cadaveric pancreata were cultured for four days in Miami media 1A. Following trypsinization, cells were isolated using anti-CD133 immunomagnetic beads to >95% CD133+. CD133-negative cells were further depleted of CD133+ cells to <1% CD133+.

2016-01-15 | E-GEOD-64854 | biostudies-arrayexpress

Functional and genetic heterogeneity of distinctive leukaemic stem cell populations in CD34- human Acute Myeloid Leukaemia

Project description:We performed RNA-sequencing of normal haematopoietic stem cells and progenitor populations and of Leukemic Stem Cells in CD34- Acute Myeloid Leukaemia.

2016-06-22 | E-MTAB-2672 | biostudies-arrayexpress

Physiologic Hypoxia Promotes Maintenance of CML Stem Cells Despite Effective BCRM-bM-^HM-^RABL1 Inhibition

Project description:ABL1 kinase inhibitors such as imatinib mesylate (IM) are effective in managing chronic myelogenous leukemia (CML) but incapable of eliminating leukemia stem cells (LSCs), suggesting that kinaseM-bM-^HM-^Rindependent pathways support LSC survival. Given that the bone marrow hypoxic microenvironment supports hematopoietic stem cells, we investigated if hypoxia similarly contributes to LSC persistence. Importantly, we found that while BCRM-bM-^HM-^RABL1 kinase remained effectively inhibited by IM under hypoxia, apoptosis became partially suppressed. Furthermore, hypoxia enhanced the clonogenicity of CML cells, as well as their efficiency in repopulating immunodeficient mice, both in the presence and absence of IM. HIF1M-bM-^HM-^RM-NM-1, which is the master regulator of the hypoxia transcriptional response is expressed in the bone marrow specimens of CML individuals. In vitro, HIF1M-bM-^HM-^RM-NM-1 is stabilized during hypoxia and its expression and transcriptional activity can be partially attenuated by concurrent IM treatment. Expression analysis demonstrates at the whole transcriptome level that hypoxia and IM regulate distinct subsets of genes. Functionally, knockdown of HIF1M-bM-^HM-^RM-NM-1 abolished the enhanced clonogenicity during hypoxia. Taken together, our results suggest that in the hypoxic microenvironment, HIF1M-bM-^HM-^RM-NM-1 signaling supports LSC persistence independently of BCRM-bM-^HM-^RABL1 kinase activity. Thus targeting HIF1M-bM-^HM-^RM-NM-1 and its pathway components may be therapeutically important for the complete eradication of LSCs. 24 samples consisting CD34+ bone marrow aspirates of 3 chronic phase patients that were subjected to 24h or 96h of DMSO/Normoxia (21% oxygen, 5% carbon dioxide) control, 2 M-BM-5M Imatinib, hypoxia (0.5% oxygen, 5% carbon dioxide) or combined Imatinib/hypoxia treatments in triplicate cultures.

2014-06-03 | E-GEOD-48294 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data